OPM-Magnetoencephalography Research in Children with Immune-Mediated Neurological Diseases
A study was planned to enroll 90 children aged 2 to 16 diagnosed with immune-mediated neurological diseases. The aim was to detect differences in brain imaging metrics over time using OPM-MEG across three visits: baseline, 2 years, and 5 years. No results have yet been reported.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not yet shown in people
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
This research could help understand neurological changes in affected children and improve diagnostic techniques, but it does not provide conclusive findings or therapeutic efficacy at this stage.
What this does not prove
The study has not yet posted results, meaning that planned endpoints and enrolment details cannot provide insights into outcomes or efficacy.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 90 · planned enrolment
- Randomised
- Not applicable
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. autoimmune encephalitis, acute disseminated encephalomyelitis, multiple sclerosis.
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Trial registrationOPM- MEG in Non-immune And iMmune-medIated Neurological Disease ↗
Supporting passages (15)
study phasePhase: Not applicable
study designStudy type: Interventional
subjectsParticipants: people; ages from 2 Years to 16 Years; sex All
sample sizeEnrollment: 90 participants (estimated)
population"eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g.
primary endpointPrimary endpoints: Detection of group differences over time in imaging metrics using OPM-MEG.
limitationsPlanned enrolment and endpoints are not findings.
human efficacyNo results are posted.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
randomizedAllocation: Not applicable
controlledIntervention model: Single group
interventionInterventions: OPM- Magnetoencephalography
follow upFollow-up: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3); Baseline, 2 years, 5 years; 2 years, 5 years
sample size basisEnrollment: 90 participants (estimated)
AI assessment, not yet reviewed by a person · version 2 · Community votes are separate from evidence review.